Abstract
Overview
Introduction
Based on generics use, the seven major markets may be divided into mature (the
US, Germany and the UK) and immature (France, Italy, Spain and Japan) markets,
both of which present different challenges, making the fast-growing,
high-value emerging markets a tantalizing prospect. In addition to market
expansion, acquisition and closer innovator ties represent key strategies for
industry growth.
Scope
- An overview of key events which have impacted on the generics industry in
the seven major markets.
- An insight into the strategic trends employed by the industry to sustain
growth in an increasingly competitive environment.
- An introduction to the emerging markets, as the next frontier for industry
growth.
- An outline of how recent M&A activity has altered the generics industry
landscape.
Report Highlights
The global generics market is growing, however it will be the immature and
emerging generics markets which will increasingly drive growth, as competitive
pressures in the more mature markets intensify, and make sustaining revenue
growth more difficult here. Consolidation continues to be a crucial strategy
for generics industry growth, with recent M&A activity having reinforced the
position of some companies, whilst bolstering the ranking of others. The
magnitude of acquisitions has also increased, and given current economic
conditions, such high price-tags may not be sustainable. The increasingly
close relationship between generics and branded companies-feared by regulators
to delay generics market entry in some cases-has reached an extreme in the
recent acquisitions of generics companies by innovators, a response to the
pressures the latter are under.
Reasons to Purchase
- Identify the issues are impacting on the generics industry in the seven
major markets.
- Understand why the emerging markets are increasingly a target for generics
companies.
- Identify the key strategic trends for the generics industry in the future.
| 
View Cart
